

November 12, 2024

BSE Limited

Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex,

Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

<u>Sub: Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants.</u>

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDI/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021.

Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended September 30, 2024 is enclosed as "Annexure A".

We request you to take the aforesaid in your records.

Thanking You.

Yours faithfully, For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

Encl: As above

Statement of Deviation or Variation for the quarter ended September 30, 2024

Name of listed entity	Marksans Pharma Limited		
Mode of Fund Raising	Preferential Issue		
Date of Raising Funds	20.07.2021 & 18.01.2023		
Amount Raised	Rs. 3,72,39,99,976.00		
Report filed for quarter ended	September 30, 2024		
Monitoring Agency	Not Applicable		
Monitoring Agency Name, if applicable	Not Applicable		
Is there a Deviation / Variation in use of funds raised	No		
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable		
If Yes, Date of shareholder Approval	Not Applicable		
Explanation for the Deviation / Variation	Not Applicable		
Comments of the Audit Committee after review	No Comments		
Comments of the auditors, if any	No Comments		

Original Object	Modified Object, if any	Original Allocatio n as on 18 th Januar y, 2023 In Rs.	Modified allocation , if any	Funds utilised till September 30, 2024 In Rs.	Amount of deviation/ variation for the quarter according to applicable object	Remarks if any
The proceeds of the preferential issue are proposed to be used to strengthen the capital base and toenhance long term financial resources of the Company in order to fund expansion program of the Company.	None	Rs. 3,72,39,9 9,976.00	None	2,48,40,55, 684.00	-	No deviations



Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

MUMBAI-53

Name of Signatory - Harshavardhan Panigrahi

Designation - Company Secretary & Compliance Officer